Global Anti-Tumor Drugs Market by Indications (Breast Cancer, Leukemia, Lung Cancer), Route of Administration (Intra-muscular, Intraperitoneal, Intravenous), Drug Class, Distribution Channels, End User - Forecast 2024-2030- Product Image

Sale

Global Anti-Tumor Drugs Market by Indications (Breast Cancer, Leukemia, Lung Cancer), Route of Administration (Intra-muscular, Intraperitoneal, Intravenous), Drug Class, Distribution Channels, End User - Forecast 2024-2030

Report
192 Pages
March 2024
Region: Global
360iResearch™
ID: 5367839

UP TO €851EUR$875USD£729GBP OFF until Dec 31^st 2024

The Anti-Tumor Drugs Market size was estimated at USD 34.89 billion in 2023, USD 39.14 billion in 2024, and is expected to grow at a CAGR of 12.24% to reach USD 78.35 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Anti-Tumor Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anti-Tumor Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Anti-Tumor Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Cybrexa Therapeutics, Dr. Reddy’s Laboratories Ltd., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genentech, Inc., Getwell Oncology, GLS Pharma Pvt. Ltd., Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd, Pfizer Inc., PharmaMar, Sanofi SA, Taiho Oncology, Inc, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.

Market Segmentation & Coverage

This research report categorizes the Anti-Tumor Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Indications
- Breast Cancer
- Leukemia
- Lung Cancer
- Melanoma
- Prostate Cancer
Route of Administration
- Intra-muscular
- Intraperitoneal
- Intravenous
- Intraventricular or Intrathecal
- Intravesicular
- Oral
- Subcutaneous
- Topical
Drug Class
- Cytotoxics
- Hormonal Therapy
- Targeted Therapy
  - Monoclonal Antibodies
  - Small Molecule Inhibitors
Distribution Channels
- Hospital Pharmacies
- Retail Pharmacies
End User
- Clinics
- Hospitals
- Specialty Centers

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

What is the market size and forecast of the Anti-Tumor Drugs Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anti-Tumor Drugs Market?
What are the technology trends and regulatory frameworks in the Anti-Tumor Drugs Market?
What is the market share of the leading vendors in the Anti-Tumor Drugs Market?
Which modes and strategic moves are suitable for entering the Anti-Tumor Drugs Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Anti-Tumor Drugs Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rise in incidence of cancer with the surge in the geriatric population
5.1.1.2. Growing awareness regarding early diagnosis and treatment for the cancer
5.1.1.3. Increase in expenditures on healthcare by government
5.1.2. Restraints
5.1.2.1. High cost of anticancer drugs and low survival rate
5.1.3. Opportunities
5.1.3.1. Availability of pipelined drugs and upsurge in demand for personalized medicines for the tumor treatment
5.1.3.2. Recent innovations in anticancer therapies
5.1.4. Challenges
5.1.4.1. Unfavorable outcomes associated with the use of cancer drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Anti-Tumor Drugs Market, by Indications

6.1. Introduction
6.2. Breast Cancer
6.3. Leukemia
6.4. Lung Cancer
6.5. Melanoma
6.6. Prostate Cancer

7. Anti-Tumor Drugs Market, by Route of Administration

7.1. Introduction
7.2. Intra-muscular
7.3. Intraperitoneal
7.4. Intravenous
7.5. Intraventricular or Intrathecal
7.6. Intravesicular
7.7. Oral
7.8. Subcutaneous
7.9. Topical

8. Anti-Tumor Drugs Market, by Drug Class

8.1. Introduction
8.2. Cytotoxics
8.3. Hormonal Therapy
8.4. Targeted Therapy
8.5.1. Monoclonal Antibodies
8.5.2. Small Molecule Inhibitors

9. Anti-Tumor Drugs Market, by Distribution Channels

9.1. Introduction
9.2. Hospital Pharmacies
9.3. Retail Pharmacies

10. Anti-Tumor Drugs Market, by End User

10.1. Introduction
10.2. Clinics
10.3. Hospitals
10.4. Specialty Centers

11. Americas Anti-Tumor Drugs Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Anti-Tumor Drugs Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Anti-Tumor Drugs Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player

15. Competitive Portfolio

15.1. Key Company Profiles
15.1.1. AbbVie Inc.
15.1.2. Amgen inc.
15.1.3. Astellas Pharma Inc.
15.1.4. AstraZeneca PLC
15.1.5. Bayer AG
15.1.6. Biogen Inc.
15.1.7. Bristol-Myers Squibb Company
15.1.8. Celgene Corporation
15.1.9. Cybrexa Therapeutics
15.1.10. Dr. Reddy’s Laboratories Ltd.
15.1.11. Eisai Co., Ltd.
15.1.12. Eli Lilly and Company
15.1.13. F. Hoffmann-La Roche Ltd
15.1.14. Genentech, Inc.
15.1.15. Getwell Oncology
15.1.16. GLS Pharma Pvt. Ltd.
15.1.17. Merck & Co., Inc.
15.1.18. Novartis AG
15.1.19. Otsuka Pharmaceutical Co., Ltd
15.1.20. Pfizer Inc.
15.1.21. PharmaMar
15.1.22. Sanofi SA
15.1.23. Taiho Oncology, Inc
15.1.24. Takeda Pharmaceutical Company Limited
15.1.25. Teva Pharmaceutical Industries Ltd.
15.2. Key Product Portfolio

16. Appendix

16.1. Discussion Guide
16.2. License & Pricing

List of Figures

FIGURE 1. ANTI-TUMOR DRUGS MARKET RESEARCH PROCESS
FIGURE 2. ANTI-TUMOR DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. ANTI-TUMOR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. ANTI-TUMOR DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. ANTI-TUMOR DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ANTI-TUMOR DRUGS MARKET DYNAMICS
FIGURE 7. ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2023 VS 2030 (%)
FIGURE 8. ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 10. ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 12. ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2030 (%)
FIGURE 14. ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 16. ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. ANTI-TUMOR DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 26. ANTI-TUMOR DRUGS MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. ANTI-TUMOR DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. ANTI-TUMOR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 6. ANTI-TUMOR DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. ANTI-TUMOR DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. ANTI-TUMOR DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. ANTI-TUMOR DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. ANTI-TUMOR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 12. ANTI-TUMOR DRUGS MARKET SIZE, BY INTRA-MUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVENTRICULAR OR INTRATHECAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVESICULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. ANTI-TUMOR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. ANTI-TUMOR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. ANTI-TUMOR DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 21. ANTI-TUMOR DRUGS MARKET SIZE, BY CYTOTOXICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. ANTI-TUMOR DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 25. ANTI-TUMOR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. ANTI-TUMOR DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 28. ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. ANTI-TUMOR DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 31. ANTI-TUMOR DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. ANTI-TUMOR DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 54. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 56. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 57. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 58. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 59. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 60. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 62. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 63. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 64. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 72. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 79. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 80. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 83. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 84. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 86. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 89. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 90. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 92. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 94. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 95. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 96. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 98. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 100. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 101. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 102. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 104. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 106. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 107. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 108. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 110. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 113. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 114. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 116. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 119. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 120. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 122. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 124. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 125. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 126. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 128. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 130. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 131. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 132. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 134. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 136. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 137. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 138. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 140. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 142. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 143. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 144. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 146. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 148. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 149. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 150. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 158. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 159. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 161. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 162. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 163. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 165. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 167. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 168. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 169. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 171. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 173. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 174. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 175. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 177. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 179. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 180. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 181. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 183. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 185. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 186. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 187. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 189. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 191. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 192. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 193. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 195. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 197. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 198. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 199. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 213. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 215. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 216. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 217. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 219. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 221. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 222. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 223. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 225. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 227. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 228. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 229. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 249. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 250. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 251. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 252. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 253. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 267. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 269. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 270. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 271. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 280. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 282. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 284. ANTI-TUMOR DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 285. ANTI-TUMOR DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 286. ANTI-TUMOR DRUGS MARKET LICENSE & PRICING

Companies Mentioned

AbbVie Inc.
Amgen inc.
Astellas Pharma Inc.
AstraZeneca PLC
Bayer AG
Biogen Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Cybrexa Therapeutics
Dr. Reddy’s Laboratories Ltd.
Eisai Co., Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Genentech, Inc.
Getwell Oncology
GLS Pharma Pvt. Ltd.
Merck & Co., Inc.
Novartis AG
Otsuka Pharmaceutical Co., Ltd
Pfizer Inc.
PharmaMar
Sanofi SA
Taiho Oncology, Inc
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	192
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 39.14 Billion
Forecasted Market Value ( USD ) by 2030	$ 78.35 Billion
Compound Annual Growth Rate	12.2%
Regions Covered	Global
No. of Companies Mentioned	25

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3283EUR$3,374USD£2,812GBP €3648EUR$3,749USD£3,125GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4159EUR$4,274USD£3,562GBP €4621EUR$4,749USD£3,958GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€5034EUR$5,174USD£4,313GBP €5594EUR$5,749USD£4,792GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5910EUR$6,074USD£5,063GBP €6567EUR$6,749USD£5,625GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7661EUR$7,874USD£6,563GBP €8513EUR$8,749USD£7,292GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects

The report addresses key questions such as

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Global Anti-Tumor Drugs Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

Anti-Neoplastic Agents Global Market Report 2024

Solid Tumor Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

Anticancer Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

Global Injectable Cytotoxic Drugs Market Analysis & Forecast to 2024-2034